Antibody-drug conjugates used in breast cancers | Oncology 2022

Advancing the Frontier: Novel Immunotherapies for Breast Cancer TreatmentПодробнее

Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate...Подробнее

Emerging Experts: A Discussion With Tarantino on HER2-Low Breast Cancer and Antibody-Drug ConjugatesПодробнее

IAPM Kerala Webinar 2024 | Update on Carcinoma Breast | Updates in treatment of Carcinoma BreastПодробнее

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugateПодробнее

【HER2 inhibitors】Trastuzumab(Herceptin®), Pertuzumab, Lapatinib, Antibody-drug conjugates (KADCYLA®)Подробнее

Breast Cancer Update and Lymphedema Education - October 2022Подробнее

Antibody-Drug Conjugates into the Management of HR+ and Triple-Negative Metastatic Breast CancerПодробнее

The Latest in Gynecologic Cancers: The ABCs of ADCs (antibody-drug conjugates)Подробнее

SABCS 2022: New breast cancer treatmentsПодробнее

HER2-Low Breast Cancer: DESTINY or Good Science?Подробнее

ESMO 2023 Breast Cancer Highlights – Keynote 756, TROPION-Breast01, Keynote 52 | Onc BrothersПодробнее

The 2023 OncoAlert Colloquium (Breast Cancer)Подробнее

ADC’s - What Everyone with MBC Should Know about Antibody Drug ConjugatesПодробнее

Antibody Drug Conjugates Present and Future Applications in Breast CancerПодробнее

Where are we in sequencing ADCs in HR+ breast cancer?Подробнее

Research Month: Antibody Drug Conjugates in Breast CancerПодробнее

ADCs in Breast Cancer: Bridging Global Vision with Indian ExperiencesПодробнее

Antibody–Drug Conjugates for Solid Tumors: Progress, Possibilities, and Implications for CareПодробнее

Revolutionizing Solid Tumor Treatment: Unleashing the Potential of Antibody-Drug ConjugatesПодробнее